Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1625 1628 1655 1699
This examiner grants 39% of resolved cases
Amy Lynn Clark serves in Tech Center 1600 and Art Unit 1600. This examiner has handled 923 resolved cases, resulting in an allowance rate of 39.1 percent. This percentage indicates the frequency of successful outcomes for patent applicants. The median days to allowance stands at 1491, suggesting that the prosecution process requires significant time and persistence from practitioners.
A notable data point is the interview lift of 31.2 percent. This figure represents an increase in the probability of securing a patent after conducting an interview with the examiner. For applications assigned to this unit, the 31.2 percent lift suggests that verbal communication can clarify technical issues that written responses might not resolve.
The 923 resolved cases provide a large sample size for evaluating these trends. The 1491 days median to allowance reflects the time commitment needed for cases in this tech center. Practitioners should prepare for this duration while leveraging the 39.1 percent allowance rate and the interview lift to improve their chances of success. The combination of these metrics defines the current prosecution landscape for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18291529 | SRPK INHIBITORS | Non-Final OA | Merck Patent GmbH |
| 18575739 | METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19 | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18687609 | CRYSTALLINE FORMS OF BIARYL YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Non-Final OA | Novartis AG |
| 18687558 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | Non-Final OA | University of South Florida |
| 18718844 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | Non-Final OA | AstraZeneca AB |
| 18577263 | Mature-Hepatocyte Transdifferentiation Suppressing Composition | Non-Final OA | OSAKA UNIVERSITY |
| 18697424 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF | Non-Final OA | XIZANG HAISCO PHARMACEUTICAL CO., LTD. |
| 17416367 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | Final Rejection | Sage Therapeutics, LLC |
| 18387913 | PPARG INVERSE AGONISTS AND USES THEREOF | Non-Final OA | Flare Therapeutics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy